Evan A. Thackaberry
Corporate Officer/Principal at VIGIL NEUROSCIENCE, INC.
Net worth: 3 870 $ as of 30/04/2024
Profile
Evan A.
Thackaberry is currently the Senior Vice President & Head-Early Development at Vigil Neuroscience, Inc. Prior to this, he worked as the Vice President-Non Clinical Development at Ra Pharmaceuticals, Inc. from 2017 to 2020.
Thackaberry holds a doctorate degree from the University of Wisconsin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0.00% | 01/03/2023 | 1,500 ( 0.00% ) | 3 870 $ | 30/04/2024 |
Evan A. Thackaberry active positions
| Companies | Position | Start |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Corporate Officer/Principal | 01/09/2020 |
Former positions of Evan A. Thackaberry
| Companies | Position | End |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2020 |
Training of Evan A. Thackaberry
| University of Wisconsin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Evan A. Thackaberry
